# ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

> **NCT06578286** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 44 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ARX788

## Key facts

- **NCT ID:** NCT06578286
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06578286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06578286, "ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06578286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*